Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 57s
Articles
Role of PGC-1-alpha-associated Mitochondrial Biogenesis in Statin-induced Myotoxicity
Citation:
European Cardiology Review 2020;15:e35.
- Views:
4
- Downloads:
0
Statins and Insulin Resistance
Citation:
European Cardiology Review 2020;15:e44.
- Views:
4
- Downloads:
0
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS study
Citation:
European Cardiology Review 2018;13(2):115–8.
- Views:
679
- Downloads:
0
Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians Different from Caucasians?
Citation:
European Cardiology Review 2018;13(2):112–4.
- Views:
259
- Downloads:
0